维生素D联合孟鲁司特对咳嗽变异性哮喘患儿的临床疗效及对IL-17与Treg的影响分析

doi:10.3969/j.issn.1006-6233.2022.05.036

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1194 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the clinical efficacy of vitamin D (VD) combined with montelukast in children with cough variant asthma (CVA) and its effect on interleukin-17 (IL-17) and regulatory T cells (Treg). Methods: Two hundred and forty-four children with CVA treated in our hospital from September 2019 to May 2021 were prospectively selected as the research objects and divided into control group (n = 61), montelukast group (n = 61), VD group (n = 61) and combined group (n = 61) through simple random method and random number table. Children in the control group were treated with routine treatment, and the other three groups were given montelukast, VD and their combination respectively for 12 weeks on the basis. The clinical efficacy and pulmonary function [including forced expiratory volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF)] and the levels of blood IL-17, CD₄⁺CD₂₅⁺Treg cells were compared among four groups. Results: The remission time and disappearance time of cough in combined group were significantly lower than those in control group, montelukast group and VD group (P<0.05). There were no significant differences in baseline data, FEV1, FVC, PEF, blood IL-17, CD₄⁺CD₂₅⁺ Treg cell levels and the incidence of adverse reactions among four groups before treatment (P>0.05). The levels of FEV1, FVC, PEF, blood CD₄⁺CD₂₅⁺Treg cells after treatment in four groups were significantly higher than those before the intervention, and the blood level of IL-17 was significantly lower than those before the intervention (P<0.05), and the application effect of the combined group was better than that of the other three groups (P<0.05). Analysis of factorial variance showed that montelukast and VD intervention were helpful to reduce cough remission time, cough disappearance time and IL-17, and increase FEV1, FVC, PEF and CD₄⁺CD₂₅⁺ Treg (P<0.05), and there was no interaction between them (P>0.05). Conclusion: VD combined with montelukast could significantly promote the remission of cough and improve lung function in children with CVA, which can be related to correcting Th17/Treg imbalance.

Key words： Cough variant asthma Vitamin D Montelukast Interleukin-17 Regulatory T cells

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YUE Jingwei
	WANG Yan
	ZHANG Min

Cite this article:

YUE Jingwei,WANG Yan,ZHANG Min. Clinical Efficacy of Vitamin D Combined with Montelukast in Children with Cough Variant Asthma and Its Effect on IL-17 and Treg[J]. HeBei Med, 2022, 28(5): 873-876.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2022.05.036 OR http://www.hbyxzzs.cn/EN/Y2022/V28/I5/873

[1] 朱晓弘,涂金伟,代继宏.丙酸氟替卡松、孟鲁斯特钠、酮替芬治疗儿童咳嗽变异性哮喘的临床疗效观察[J].中国当代儿科杂志,2019,21(4):393~398.
[2] 谢坤霞,马晓鹏,任华.布地奈德联合孟鲁司特钠对咳嗽变异性哮喘患儿炎症反应及症状积分的影响[J].贵州医药,2019,43(9):1394~1395.
[3] 贾金华,刘婷婷,马丹.维生素D3辅助治疗咳嗽变异性哮喘患儿的疗效观察[J].中国现代应用药学,2019,36(19):2460~2463.
[4] 傅榕冰,魏义杰,虎春艳,等.五宝胶囊对哮喘小鼠肺泡灌洗液中Th1/Th2、Th17/Treg失衡及趋化因子的影响[J].中国比较医学杂志,2020,30(3):1~7.
[5] 中华医学会儿科学分会呼吸学组,《中华儿科杂志》编辑委员会.儿童支气管哮喘诊断与防治指南(2016年版)[J].中华儿科杂志,2016,54(3):167~181.
[6] 李雯,赵伟伟,葛建敏,等.百蕊颗粒联合阿奇霉素及布地奈德雾化吸入治疗对咳嗽变异性哮喘患儿肺功能和炎症因子的影响[J].现代生物医学进展,2020,20(16):3156~3159.
[7] 徐青.布地奈德联合孟鲁司特对支气管哮喘患者外周血IL-33IL-17A及诱导痰炎性因子的影响[J].河北医学,2020,26(3):362~366.
[8] 王宽锋,任华,王翠翠,等.孟鲁司特钠联合布地奈德雾化吸入对咳嗽变异性哮喘患儿肺功能的影响[J].实用临床医药杂志,2019,23(4):41~43,46.
[9] 闫利霞.咳嗽变异性哮喘患儿血清25羟基维生素D3、免疫球蛋白E、血清淀粉样蛋白A水平与预后的相关性[J].中国临床医生杂志,2020,48(9):1102~1104.
[10] 黄羽,刘瑛.孟鲁司特对咳嗽变异性哮喘患儿Treg及Th17相关细胞因子表达的影响[J].昆明医科大学学报,2019,40(6):125~128.
[11] 胡翠萍.维生素D对哮喘儿童Th1/Th2/Th17/Treg免疫失衡的影响研究[J].中国预防医学杂志,2019,20(4):357~360.